Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 May 30;14(5):2553-2557.
doi: 10.21037/tcr-2024-2516. Epub 2025 May 12.

Microsatellite instability (MSI) and the tumor mutation burden (TMB) as biomarkers of response to immune checkpoint inhibitors in prostate cancer

Ioannis A Voutsadakis  1   2
Affiliations
Editorial

Microsatellite instability (MSI) and the tumor mutation burden (TMB) as biomarkers of response to immune checkpoint inhibitors in prostate cancer

Ioannis A Voutsadakis. Transl Cancer Res. .
No abstract available

Keywords: Microsatellite instability (MSI); immune checkpoint inhibitors; prostate cancer; tumor mutation burden (TMB).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-2024-2516/coif). The author has no conflicts of interest to declare.

Comment on

References

    1. Thein KZ, Myat YM, Park BS, et al. Target-Driven Tissue-Agnostic Drug Approvals-A New Path of Drug Development. Cancers (Basel) 2024;16:2529. 10.3390/cancers16142529 - DOI - PMC - PubMed
    1. Jardim DL, Goodman A, de Melo Gagliato D, et al. The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell 2021;39:154-73. 10.1016/j.ccell.2020.10.001 - DOI - PMC - PubMed
    1. Németh E, Szüts D. The mutagenic consequences of defective DNA repair. DNA Repair (Amst) 2024;139:103694. 10.1016/j.dnarep.2024.103694 - DOI - PubMed
    1. Lu C, Guan J, Lu S, et al. DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. Cancer Cell 2021;39:96-108.e6. 10.1016/j.ccell.2020.11.006 - DOI - PMC - PubMed
    1. Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 2017;9:34. 10.1186/s13073-017-0424-2 - DOI - PMC - PubMed